TDF + Placebo Vaginal Gel + Vaginal TFV Gel + Placebo Tablets
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Herpes Simplex Type II
Conditions
Herpes Simplex Type II
Trial Timeline
Feb 1, 2012 → Jun 1, 2015
NCT ID
NCT01448616About TDF + Placebo Vaginal Gel + Vaginal TFV Gel + Placebo Tablets
TDF + Placebo Vaginal Gel + Vaginal TFV Gel + Placebo Tablets is a approved stage product being developed by Gilead Sciences for Herpes Simplex Type II. The current trial status is completed. This product is registered under clinical trial identifier NCT01448616. Target conditions include Herpes Simplex Type II.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01448616 | Approved | Completed |
Competing Products
20 competing products in Herpes Simplex Type II